🧬 SinoBioData Academic Portal
Open AccessDOI: 10.12307/2026.21611Original Research

Epidemiological association between metabolic health obesity phenotype and chronic low back pain: a cross-sectional analysis based on the NHANES database

Ye Shicheng¹,Liu Yuxin¹,Zeng Xuan¹,Sui Lili¹,Liu Jiao¹,Chen Yuting¹,Qu Chongzheng¹

Third Clinical Medical College, Guangzhou University of Chinese Medicine

Read Executive PreviewQuick FAQ
Epidemiological association between metabolic health obesity phenotype and chronic low back pain: a cross-sectional analysis based on the NHANES database
Graphical Abstract / Figure
Published In
Chinese Journal of Tissue Engineering Research
Published:January 15, 2026Edition:Vol 1908, Issue 36 • pp. 100-112Citation:Ye Shicheng et al. (2026), Chinese Journal of Tissue Engineering Research
Impact FactorPremier Chinese Biomedical Journal indexed in SinoBioData: Chinese Journal of Tissue Engineering Research (中国组织工程研究).
Sponsored Research Partner

Key Takeaways & Executive Findings

  • • Metabolically unhealthy obesity significantly increases chronic low back pain risk (OR=1.44-1.57), while metabolically healthy obesity shows no significant association. • Smoking and arthritis amplify the risk of chronic low back pain in metabolically healthy obese individuals. • BMI ≥39.73 kg/m² and waist circumference ≥125 cm are risk thresholds for chronic low back pain in metabolically unhealthy individuals. • Metabolic health status is a key factor in obesity-related chronic low back pain, suggesting targeted interventions for metabolically unhealthy obesity.
Sponsored Research Highlight

Abstract

BACKGROUND: Currently, whether and how the metabolically healthy obesity phenotype influences the risk and pathological progression of chronic low back pain compared to metabolically unhealthy obese individuals remain unclear. Research is urgently needed to clarify their association and potential mechanisms. OBJECTIVE: To investigate the epidemiological association between the metabolically healthy obesity phenotype and chronic low back pain. METHODS: Using data from the US National Health and Nutrition Examination Survey (NHANES) 1999-2004 and 2009-2010 (n=4,956), a retrospective cross-sectional study was conducted. Obesity was defined by body mass index and waist circumference according to WHO standards, and metabolic phenotype was stratified using core metabolic syndrome indicators (fasting glucose, lipid profile, blood pressure, etc.), establishing metabolically healthy obesity and metabolically unhealthy obesity classification. Multivariable-adjusted logistic regression models and restricted cubic spline curves were used to systematically evaluate the nonlinear dose-response relationship between metabolic health obesity phenotype and chronic low back pain risk. Multivariable-adjusted models were established to analyze chronic low back pain risk, and subgroup analysis, threshold effect analysis, and multiple sensitivity analyses were used to verify model robustness. RESULTS AND CONCLUSION: (1) Metabolically unhealthy obesity significantly increased the risk of chronic low back pain [BMI standard: OR (95%CI)=1.44 (1.11, 1.85), P=0.0070; waist circumference standard: OR (95%CI)=1.57 (1.25, 1.97), P=0.0003]. Smoking [OR (95%CI)=1.44 (1.24, 1.67), P<0.0001] and arthritis [OR (95%CI)=2.44 (2.06, 2.88), P<0.0001] significantly amplified the risk effect of metabolically healthy obesity on chronic low back pain. BMI ≥39.73 kg/m² and waist circumference ≥125 cm were risk thresholds for chronic low back pain in metabolically unhealthy individuals. Low education level, low income, and widowed/divorced or separated status increased the risk of chronic low back pain. In the total population and metabolically unhealthy participants, there was a linear relationship between BMI and chronic low back pain (P<0.05). In metabolically healthy participants, the dose-response relationship between BMI and chronic low back pain was approximately linear (P>0.05); in the total population, metabolically healthy and metabolically unhealthy participants, the dose-response relationship between waist circumference and chronic low back pain was approximately linear (P>0.05). (2) Based on NHANES cross-sectional analysis, metabolically unhealthy obesity was significantly and positively independently associated with chronic low back pain, while metabolically healthy obesity had a weaker and non-statistically significant association, indicating that metabolic health status is an important factor influencing chronic low back pain in obese individuals. The model constructed from international research provides a key theoretical reference for exploring racial heterogeneity and localized mechanisms (such as Asian-specific metabolic thresholds) in the Chinese population. The results warn that China should pay attention to the risk of low back pain in metabolically healthy obese individuals, promote optimized clinical classification intervention strategies (such as avoiding excessive weight loss), and prospectively prevent the public health burden of obesity-related musculoskeletal diseases.

1. Introduction

Chronic low back pain is not only the most common type of musculoskeletal disorder but also a leading cause of disability globally. According to the Global Burden of Disease Study 2021, 619 million people worldwide are affected by chronic low back pain, with projections indicating a 36.4% increase by 2050 [1]. This condition consumes substantial healthcare resources [2-3].

Obesity, defined as a body mass index (BMI) ≥30 kg/m², has become a severe global health issue, particularly in the United States where the age-adjusted prevalence is 42.4% [4]. Evidence suggests that obesity leads to numerous complications, including diabetes, cardiovascular disease, hypertension, cancer, and musculoskeletal pain, and has been established as an independent risk factor for chronic low back pain [5-9]. Studies have highlighted that obesity increases the risk of lower trunk musculoskeletal pain [10-11]. Previous research indicates that obesity coexists with metabolic abnormalities, and obesity-related metabolic disorders can mediate the incidence of obesity-related diseases [12]. Moreover, the pathological mechanisms of chronic low back pain exhibit significant metabolic interactions with obesity [13]. Smith et al. [14] showed that if health is defined as the absence of metabolic syndrome, approximately 50% of obese patients can be considered metabolically healthy; however, when health is defined as having no metabolic syndrome components and normal insulin sensitivity assessed by insulin resistance indices, only about 5% of obese patients meet the criteria. Cohort studies have also shown that metabolically healthy obese individuals have a lower risk of cardiovascular events compared to metabolically unhealthy obese individuals, but the relationship with chronic low back pain remains unclear.

SinoBioData Interactive Document Reader
Page 1–5 of Preview
100%
Download Full PDF

Loading authentic research manuscript (Pages 1–5)...

Sponsored Research Partner
Cite This Research Paper
Ye Shicheng, Liu Yuxin, Zeng Xuan, Sui Lili, Liu Jiao, Chen Yuting, Qu Chongzheng (2026). Epidemiological association between metabolic health obesity phenotype and chronic low back pain: a cross-sectional analysis based on the NHANES database. Chinese Journal of Tissue Engineering Research. https://doi.org/10.12307/2026.21611
SinoBioData Academic & Legal Disclaimer

Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.

Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.

Frequently Asked Questions

What is the metabolic health obesity phenotype?

Metabolic health obesity phenotype refers to obese individuals who do not have metabolic syndrome components such as insulin resistance, dyslipidemia, or hypertension. They typically have lower visceral fat, preserved insulin sensitivity, and lower inflammation compared to metabolically unhealthy obese individuals.

How does metabolically unhealthy obesity affect chronic low back pain risk?

The study found that metabolically unhealthy obesity significantly increases the risk of chronic low back pain, with odds ratios of 1.44 (BMI standard) and 1.57 (waist circumference standard) compared to metabolically healthy non-obese individuals.

What are the risk thresholds for chronic low back pain in metabolically unhealthy individuals?

The study identified BMI ≥39.73 kg/m² and waist circumference ≥125 cm as thresholds beyond which the risk of chronic low back pain significantly increases in metabolically unhealthy individuals.

Does metabolically healthy obesity increase chronic low back pain risk?

The study found no statistically significant association between metabolically healthy obesity and chronic low back pain, suggesting that metabolic health status is a key factor in obesity-related low back pain.

What are the implications for clinical practice?

The findings suggest that interventions should focus on improving metabolic health in obese individuals rather than solely on weight loss, and that metabolically unhealthy obese individuals should be prioritized for prevention and management of chronic low back pain.

Recommended Scientific Literature & Research Partners

Related Technical Papers & Translations

Research Paper
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis

Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis

Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.

Read Abstract & PDF
Research Paper
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials

Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials

Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.

Read Abstract & PDF
Research Paper
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis

Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis

Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.

Read Abstract & PDF